|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.318 SEK | -0.90% |
|
+1.54% | -24.03% |
Sprint Bioscience AB (publ) reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported sales was SEK 0.014 million compared to SEK 0.73 million a year ago. Revenue was SEK 0.348 million compared to SEK 0.748 million a year ago.
Net loss was SEK 14.8 million compared to SEK 15.04 million a year ago. Basic loss per share from continuing operations was SEK 0.3 compared to SEK 0.38 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -24.03% | 8.46M | |
| -1.65% | 104B | |
| +6.75% | 97.47B | |
| +5.71% | 22.25B | |
| -12.60% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.17% | 16.36B | |
| +6.12% | 14.39B | |
| +35.47% | 12.37B |
SPRINT BIOSCIENCE AB 
